Gilbert Tang, MD, surgical director of the structural heart program at the Mount Sinai Health System, discussed a key challenge care teams often encounter during tricuspid valve procedures. 

The pressure changes associated with contrast injections are minimal, researchers noted, especially once you move away from the tip of the catheter. 

Charles E. Mullins, MD, a U.S. Army veteran who went on to practice medicine for five decades, died at the age of 92. SCAI shared a loving tribute to Mullins, calling him the "father of modern interventional pediatric cardiology."

The Sapien 3 Ultra Resilia TAVR valve from Edwards Lifesciences is associated with a significantly higher survival rate after one year than the company's previous balloon-expandable valves. Researchers identified other key benefits as well, sharing their findings in JACC: Cardiovascular Interventions.

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

SCAI celebrated cardiologists William W. O'Neill, MD, and Cindy L. Grines, MD, for the important roles they played in the development of primary PCI. “It was challenging,” Grines explained. “We had the pharmaceutical industry that was anti-primary angioplasty and we had a lot of our own colleagues that were anti-primary angioplasty."

Self-expanding and balloon-expandable TAVR valves are associated with comparable success rates and one-year outcomes when treating type 1 bicuspid aortic stenosis. However, each valve type comes with its own advantages and disadvantages.